Interview guides · Boehringer Ingelheim

Boehringer Ingelheim Data Scientist Interview Questions & Guide 2026

Boehringer Ingelheim data scientist prep: probability, sampling distributions, and stating the assumption behind every test you run.

The 60-second brief

As a Data Scientist at Boehringer Ingelheim, you play a pivotal role in transforming data into actionable insights that drive decision-making and innovation within the company. This position is not just about analyzing data; it's about understanding complex biological processes and leveraging data-driven methodologies to enhance patient outcomes and streamline operations in the pharmaceutical industry. Your contributions will be essential in supporting research and development initiatives, optimizing clinical trials, and informing product strategies that could impact millions of lives.

Product-sense cases reward reasoning from a mechanism to a testable prediction. Reciting every metric you can name reads as pattern matching; naming the single quantity that would move if your explanation were true reads as thinking.

Focus areas

Build member-month denominators from overlapping coverage spans
Reconstruct drug exposure intervals from dispensing records
Risk-adjust outcomes before comparing providers or panels

Overview

The role demands a unique blend of technical expertise and domain knowledge, as you will work closely with cross-functional teams, including research scientists, product managers, and regulatory affairs professionals. Projects may include developing predictive models to assess drug efficacy, optimizing manufacturing processes through data analysis, or employing machine learning techniques to process large datasets. The complexity and scale of the data you will handle, combined with the strategic importance of your insights, make this position both challenging and rewarding.

The work environment at Boehringer Ingelheim is collaborative and innovative, encouraging you to think creatively and challenge the status quo. You will be at the forefront of applying advanced analytical techniques to critical business problems, making a tangible difference in the healthcare landscape.

The Boehringer Ingelheim interview process

Boehringer Ingelheim candidates report 4 rounds · ≈ 3-5 weeks. The stages below are what candidates describe, not a published process.

Phone Screening

Data Scientist covers at least four different jobs: experimentation, product analytics, causal work on observational data, and applied modelling that ships into a system. A screening call is the cheapest place to find out which of them is being hired for, and doing that diagnosis openly reads as senior rather than fussy. Ask what the last few pieces of work on the team actually were, and roughly how a week splits between querying, modelling and stakeholder time. Then say which parts of that you have done and which you have not. Claiming the whole range is the fastest way to be caught one round later.

What to demonstrate

Whether you can distinguish the flavours of the role and locate your own experience inside one of them honestly
Whether you name what you have not done instead of stretching to cover every line of the posting
Whether your hard constraints (notice period, location, work authorisation, level) surface now rather than at offer stage

How to prepare

Map the last two years of your time into rough percentages across query writing, experiment design, modelling and stakeholder work, so a question about scope has a real answer
Mark every responsibility in the posting as done, adjacent or new, and prepare one sentence for each adjacent item naming the closest thing you have actually built
Decide which logistics are non-negotiable before the call so you can state them in one sentence rather than negotiating live

Technical Interviews

This round decides whether someone can hand you a schema and a question and trust the number that comes back. Correctness under a clock is the bar, not clever syntax. The habit that separates strong from weak answers is checking the grain: after every join, know how many rows you expect and whether the count moved. Most wrong answers in this format are not wrong logic, they are a fan-out from a key that turned out not to be unique, or a filter applied before an aggregate when it belonged after. Say what you expect before you run it.

What to demonstrate

Whether your row counts survive each join, and whether you notice on your own when they do not
Deliberate handling of rows that fail to match, including whether the question needs an inner join or a left join with the non-matches kept and counted
Whether NULLs are treated on purpose, given that a NULL compares equal to nothing and that COUNT of a column skips it
Reaching a defensible answer inside the window instead of a refined one after it

How to prepare

Take a two-table schema, write a join that fans out on purpose, then fix it by collapsing the many-side to one row per key before joining. Repeat until the fix is reflex rather than recall.
Write a funnel as one query and print the distinct user count at each stage, then confirm each stage is a subset of the one above it rather than assuming it
Do a few timed runs in a plain text box with no autocomplete and no formatter, since assessment editors often have neither

Behavioral Assessments

Rounds of this kind usually include one question about work that did not go well, and it is the part that carries the most information. Anyone can narrate a shipped win. What the interviewer learns from a project that stalled is how you behave without a result to hide behind: whether you noticed the problem yourself, how long it took, and who you told. Answers that route the failure onto a data pipeline or a reorganisation close the topic without answering it, and the follow-up comes back to your own part.

What to demonstrate

Whether you found the error yourself or someone else found it, and how long it sat before anyone knew
What you changed afterwards, stated as a check you now run rather than a lesson you now believe
Whether the mistake you choose has real cost attached, such as a quarter of misdirected roadmap or a metric that was reported upward, instead of one that flatters you

How to prepare

Choose a failure you caught yourself and be ready to say what tipped you off. A story where someone else caught it is still usable, but you will be asked why you missed it.
Write down the check you added afterwards and where it lives now, so the correction is a concrete artefact rather than a resolution.
Rehearse saying the cost out loud. Candidates shrink the number by instinct once the interviewer is in the room.

Final Discussions

A day of back-to-back interviews samples your floor, not your ceiling. Four hours in, the habits that carry a good answer are the first to go: restating the question before solving it, asking what the data would have to look like, checking a number before quoting it. What the day decides is whether the tired version of you is still someone to leave alone with an ambiguous problem. The round that sinks a candidate is usually not the hardest one. It is the one immediately after the round that went badly.

What to demonstrate

Whether the late rounds get the same clarifying questions as the first one, or whether you start answering immediately to save effort
Whether a weak answer stays in the room it happened in, instead of following you into the next conversation as apology or distraction
Whether the quality of your questions holds up, since fatigue removes curiosity about the problem before it removes knowledge of the method

How to prepare

Rehearse the length, not just the content: book four mock interviews of different types in one afternoon with short gaps, because the one you need to observe is the fourth
Put the two or three questions you ask at the start of any problem on a card in front of you, so that under fatigue it is a habit you run rather than a decision you make
Decide in advance what the gap between rooms is for: water, one line of notes on anything you promised to follow up, and an explicit close on the round that just ended so it does not travel
Prepare a different closing question for each interviewer, so the end of a long day does not produce the same one four times

Where candidates lose points

Pre-post evaluation on a high-cost or high-risk cohort

Cohorts selected on an extreme value of the outcome regress toward the mean on their own. Members identified as the top 1 percent of spend in one year spend far less the next, whether or not anyone intervenes, because the selecting year captured both chronic severity and one-off events. A pre-post design on such a cohort will report savings every time. A concurrent comparison group selected by the same rule in the same period, or a regression discontinuity at the selection threshold, is the minimum credible design.

Treating clinical measurements as missing at random

A lab result, a vital sign, or a screening exists because someone ordered it, and ordering tracks suspicion of disease, visit frequency, and site workflow. Imputing the mean or dropping incomplete rows biases the population estimate and can flip the sign of an association, because the untested are systematically healthier or systematically disengaged. The presence indicator is often more predictive than the value, which is a warning sign rather than a feature win: a model that learns test ordering will not transfer to a site with different protocols.

Solving silently instead of narrating the reasoning

Say which branch you are taking and why you chose it over the alternative, for example checking the denominator first because it changes what the comparison means. A correct answer that arrives with no visible path scores below a rigorous one that needed a hint.

Averaging per-user rates to produce a population rate

Decide which quantity you want: the mean of per-user ratios and the ratio of summed numerator to summed denominator are different estimands, and heavy users dominate one but not the other. For a ratio metric, aggregate numerator and denominator separately and use the delta method for its variance.

Questions & practice

Write a function to calculate the mean and standard deviation of a given dataset.

Medium · statistics and probability

Approach

Write down the assumption the method needs before you use the method.
Sanity-check the answer against a simple bound or a simulated case.
Translate the result into the decision it informs, in one plain sentence.

Follow-up

What sample size would you need to detect an effect half this size?
Which assumption here is most likely to be violated in practice?

Bootstrap a confidence interval for a ratio-of-sums PMPM

Medium · bootstrap · ratio estimator · resampling unit

You have one row per member for a fully run-out incurred year: member_id, member_months, allowed_amount. Report allowed PMPM, defined as sum(allowed_amount) divided by sum(member_months), with a 95 percent confidence interval from a bootstrap you write yourself. No library resampler. Resample members with replacement, recompute the ratio on each of 2,000 replicates, take a percentile interval, and seed the generator so the result reproduces. In two sentences, state why resampling claim lines instead of members would be wrong.

Approach

Name the estimator precisely: PMPM is a ratio of sums, not the mean of per-member ratios. The two differ whenever exposure correlates with spend, and it does, because members who churn out mid-year are systematically different from members covered all twelve months.
Resample the unit of independence, which is the member, and recompute numerator and denominator together on the same draw. Recomputing only the numerator against a fixed denominator understates variance and is a common slip.
Pull member_months and allowed_amount into numpy arrays once, then draw indices with rng.integers(0, n, size=n) per replicate. Index draws over arrays run one to two orders of magnitude faster than DataFrame.sample, which is the difference between 2,000 replicates and 200.
Take the 2.5th and 97.5th percentiles of the replicate ratios. Expect an interval that is asymmetric around the point estimate, because healthcare spend is right skewed. That asymmetry is the method working, not a bug to centre away.
Answer the line-resampling question concretely: the many lines of one high-cost member are not independent draws, so line resampling shrinks the interval toward zero width, and member_months has no line-level analogue, so the denominator becomes undefined.

Worked solution (25 min)

Compute the point estimate as allowed.sum() / months.sum() on the full sample.
Extract both columns to float numpy arrays and create rng = np.random.default_rng(seed).
Loop 2,000 times: idx = rng.integers(0, n, n); ratio = allowed[idx].sum() / months[idx].sum(); store it.
Take np.percentile(replicates, [2.5, 97.5]) and report the point estimate with that interval and the seed.

Expected result: A point estimate plus a 95 percent percentile interval that is wider on the upper side than the lower. With tens of thousands of members and a typical commercial cost distribution the relative half-width lands on the order of a few percent; an interval a small fraction of a percent wide is the signature of having resampled rows rather than members.

Verify it yourself

Re-running with the same seed reproduces both bounds exactly.
Raising replicates from 2,000 to 8,000 moves each bound by less than its third significant figure.
The mean of the replicate ratios sits close to the point estimate; a large gap indicates a bug in the resampler rather than skew.
Replicate denominators cluster tightly around the observed total member-months, which confirms the draw size is n rather than a fixed constant.

Follow-up

Half a percent of members have a transplant or a long NICU stay. Does a percentile interval still have nominal coverage, and what would you do about the tail?
The question changes to comparing PMPM across provider panels. What becomes the resampling unit and why?
How would you use the same replicates to test whether this year's PMPM differs from last year's, given the same members appear in both?

Sessionise transfer chains into episodes, then count readmissions

Hard · sessionisation · cumsum grouping · readmission

encounter has encounter_id, patient_id, facility_id, encounter_type, admit_ts, discharge_ts, admission_type, discharge_disposition, is_planned_admission, principal_diagnosis_code. Chain acute-to-acute transfers into episodes of care: an inpatient encounter discharged as transfer_acute, followed by another inpatient encounter for the same patient at a different facility admitting within 24 hours of that discharge, belongs to the same episode. Then compute the 30-day unplanned readmission rate over episodes, excluding index episodes that are planned, that end in expired, hospice or against medical advice, or that are still open. Return encounter_id to episode_id, plus the rate.

Approach

Restrict to inpatient encounters for the chaining step and sort by patient_id, admit_ts. Observation and emergency encounters are not acute inpatient stays and pooling them changes both the chain and the denominator.
Build a boolean continues flag: the previous row is the same patient, its discharge_disposition is transfer_acute, its facility_id differs from this row's, and admit_ts minus previous discharge_ts is between 0 and 24 hours. Episode id = cumsum of the negation of that flag. This is the vectorised form of a sessionisation loop and is why the pattern generalises to any event stream.
Collapse to episode grain taking first admit_ts, last discharge_ts, last discharge_disposition, and any() of is_planned_admission. The episode inherits its exit state, not its entry state, which is why a transfer chain ending at home is one home discharge rather than two transfers.
Apply index exclusions at episode grain. Dropping episodes that end in death is not optional: a dead patient cannot be readmitted, so leaving them in inflates the denominator and depresses the rate for exactly the panels caring for the sickest members.
For each surviving index episode, find the next unplanned acute inpatient episode for that patient admitting within 30 days of the index discharge_ts. Count events at episode grain, since one patient can contribute several index episodes. Report the raw rate and say plainly that it is not comparable across panels without risk adjustment, which is what the observed-over-expected form exists for.

Follow-up

discharge_ts is null on an open stay in the middle of a chain. What does your flag do, and what should it do?
A patient is transferred out and then back to the originating facility within 24 hours. Should that chain, and does your facility_id condition handle it?
Is a readmission itself eligible to serve as a later index episode? Say what you chose and what the choice does to the rate.

How would you implement a recommendation system for a new product?

Medium · sql and data manipulation

Approach

State the window function and its partition and ordering out loud before writing it.
Check whether any join is one-to-many before aggregating, or the sums inflate.
Say which table is the grain you start from, and join outward from it.

Follow-up

What breaks if events arrive late or out of order?
How would you verify this result without re-running the same query?

Report site activation to first randomization without hiding non-enrollers

Medium · grain collapse · left join · censoring

study_site holds one row per (study_id, site_id): site_activation_date, which is NULL for a site selected but never activated, and site_status. study_subject_visit holds subject_visit_id, study_id, site_id, subject_id, randomization_ts (NULL for screen failures), visit_name, visit_number, actual_visit_date and visit_status, with one row per subject per protocol visit, so randomization_ts repeats across every visit of a randomized subject and a site that has screened nobody has no rows there at all. For one study_id and a stated data cut date, return per activated site the activation date, the first randomization_ts and the days between them, with activated sites that have randomized nobody still present. Add a study-level summary giving median days to first randomization and the share of activated sites with no randomization by day 90.

Approach

Take the site universe from study_site, never from study_subject_visit. The visit table can only contain sites that have screened at least one subject, so a universe built from DISTINCT site_id there omits exactly the sites this metric exists to expose. Filter study_site to the study and to site_activation_date IS NOT NULL, then LEFT JOIN the per-site first randomization.
Collapse the grain before aggregating anything on the visit side. The table repeats randomization_ts across every visit of a randomized subject, so any count taken at row grain is inflated by visits per subject. MIN(randomization_ts) per site is safe, COUNT is not.
State the date boundary rule. randomization_ts is a timestamp and site_activation_date is a date, so a randomization at 23:40 local time can land on either side of a day boundary depending on the zone the timestamp is stored in. Cast once, deliberately, and say which zone.
Use PERCENTILE_CONT(0.5) WITHIN GROUP (ORDER BY days) for the median and be explicit that it ignores NULLs, so it is a median over enrolling sites only. That is exactly why the non-enroller share is reported beside it rather than instead of it.
Censor the day-90 denominator against the data cut. A site activated 40 days before the cut has not had 90 days to randomize, so it cannot be scored on that bar and belongs outside that denominator.

Worked solution (25 min)

CTE sites: site_id and site_activation_date from study_site for the study where site_activation_date IS NOT NULL. The (study_id, site_id) key already gives one activation date per site, so assert that key rather than de-duplicating defensively.
CTE first_rand: site_id and MIN(randomization_ts) over study_subject_visit rows for the study where randomization_ts IS NOT NULL, grouped by site_id.
LEFT JOIN sites to first_rand and compute days_to_first_randomization with an explicit cast of the timestamp to a date.
Summary: PERCENTILE_CONT(0.5) over non-null days, plus the count and share of sites with no randomization by day 90, restricted to sites activated at least 90 days before the data cut.
Compare the site-level row count with COUNT(DISTINCT site_id) in study_subject_visit for the study; the difference is the activated sites that have screened nobody, which is the population the metric is for.

Expected result: One row per activated site with site_id, site_activation_date, first_randomization_ts and days_to_first_randomization, NULL in both randomization columns for sites that have randomized nobody, including sites with no study_subject_visit rows at all; plus one summary row with median_days_over_enrolling_sites, sites_activated_90d_or_more and share_with_no_randomization_by_day_90.

Verify it yourself

Site-level row count equals the number of study_site rows for the study with a non-null site_activation_date, and is greater than or equal to COUNT(DISTINCT site_id) in study_subject_visit for that study. Below it means either an activated site is missing from study_site or a visit row carries a site_id whose activation date is NULL, both data-quality findings.
No days_to_first_randomization is negative. A negative value is a data-quality finding to raise, not a number to clamp at zero.
The day-90 denominator excludes sites activated within 90 days of the data cut. Including them can only add sites that have not had a full 90 days, and any of those without a randomization would be miscounted as a failure.

Follow-up

The same site_id appears under two studies. What breaks, and what is the correct grain for this metric?
Would you present this as a median, as a Kaplan-Meier curve of time to first randomization, or both, and what does the curve show that the median cannot?
A site randomized one subject who withdrew at visit 2. Does that site count as enrolling here, and how does that differ from a randomized-and-retained measure?

If you were given a large dataset with missing values, what steps would you take to clean and analyze the data?

Medium · product sense and metrics

Approach

State what result would change your recommendation, so the answer is falsifiable.
Restate the decision this analysis has to support, and who acts on the answer.
Decompose the metric into the rates that drive it, and say which one you would check first.

Follow-up

Which segment would you cut first, and what would that rule out?
How would you detect that the metric is being gamed rather than genuinely improving?

How would you approach designing an experiment to test the efficacy of a new drug?

Medium · a/b testing and experimentation

Approach

State the primary metric and the minimum effect worth shipping, then size the test.
Decide the analysis before seeing data, including how long it runs and when you look.
Say whether units interfere with each other, and switch design if they do.

Follow-up

What would you conclude if the result is positive but the test is underpowered?
How would you handle interference between treated and control units?

What statistical methods are you most comfortable with, and how have you applied them in past projects?

Medium

Approach

Say what you would check first and why it is the highest-information step.
State your assumptions explicitly before working the problem.
Work from the decision backwards to the evidence you would need.

Follow-up

What assumption would you test first?
How would you know your answer was wrong?

How do you approach feature selection and engineering in your models?

Medium

Approach

Work from the decision backwards to the evidence you would need.
Say what you would check first and why it is the highest-information step.
State your assumptions explicitly before working the problem.

Follow-up

What assumption would you test first?
How would you know your answer was wrong?

Evaluate a book-wide benefit change with no untreated members

Hard · difference-in-differences · synthetic control · parallel trends · seasonality confounding

On 1 January a therapeutic class moves from formulary tier 2 to tier 3, raising member cost share, for the entire commercial group book at once. No untreated subset of that book exists. You have 36 months of pharmacy_claim and member_enrollment covering that book plus the Medicare Advantage and Medicaid managed books, which are unaffected. Outcomes are class fills per 1,000 member-months and the share of members with PDC at or above 0.80. Give the design, the identifying assumption, and how you would test it.

Approach

Rule out the single-series interrupted time series first and say why. The change lands on 1 January, which is also when deductibles reset, benefit designs change, and members switch plans, so a level shift at the new year is confounded with the entire annual benefit cycle. Any design that cannot separate those two is not usable here.
Build an event-study difference-in-differences with the unaffected product books as controls, estimating month-by-month coefficients relative to December. The lead coefficients are the test of the identifying assumption, not decoration: they should be indistinguishable from zero, and you should say in advance what magnitude of lead violation would make you abandon the design.
State what the control books are doing for you and what they are not. They experience the same January reset, which is precisely why they are useful, but they differ in population age, cost-sharing structure, and eligibility churn, so parallel counterfactual trends is a real assumption and residual confounding should be named rather than waved at.
Add a synthetic control as the robustness check: construct a weighted combination of donor series (other product books crossed with other therapeutic classes) that tracks the treated series through the pre-period, and do inference by permutation, assigning the intervention to each donor and comparing post-to-pre RMSPE ratios. Require that the treated pre-period sits inside the convex hull of the donors, and abandon the approach if pre-period fit is poor.
Fix the population before estimating anything. If the tier move pushes members out of the book, the post-period population differs from the pre-period one, so restrict to members continuously enrolled across the window with a stated allowable gap, and report sensitivity to that gap. Note that pharmacy claims adjudicate in days, so unlike a medical-cost series this outcome is essentially complete within weeks.

Worked solution (45 min)

Build a monthly panel of fills per 1,000 member-months and PDC share by product book, restricted to members continuously enrolled across the window with a 45-day allowable gap.
Plot the treated and control series for 24 pre-period months and inspect visually before fitting anything.
Estimate an event-study DiD with month-relative-to-January coefficients, product fixed effects, and calendar-month fixed effects, clustering standard errors at the product-book level or higher.
Run the placebo: re-estimate as if the change happened on the prior 1 January, which isolates the annual reset from the tier move.
Fit a synthetic control on donor product-class series, check pre-period RMSPE, and run the permutation inference across donors.

Expected result: An event-study difference-in-differences of the affected commercial book against unaffected product books on continuously enrolled members, with a synthetic control and permutation inference as the robustness check. The identifying assumption is parallel counterfactual trends, tested by null lead coefficients and by a prior-January placebo that separates the tier change from the deductible reset.

Verify it yourself

Lead coefficients in the event study should be within noise of zero across the pre-period.
The prior-January placebo should return an effect near zero; if it does not, the January reset is contaminating the estimate.
Synthetic control pre-period RMSPE should be small, and the treated unit's post-to-pre RMSPE ratio should be extreme relative to the donor distribution.
The estimate should be stable when the continuous-enrolment gap allowance moves from 0 to 45 days.

Follow-up

The lead coefficients are not flat: the treated book was already drifting down for six months. What do you do without abandoning the question?
Therapeutic substitution is expected. How do you tell a true reduction in therapy from members moving to a cheaper drug in the same class?
How would you report the result so a clinical committee can act on it, given that fills per 1,000 member-months is not an outcome anyone treats?

Protocol deviations fell as new sites came online

Hard · reporting lag · denominator mix · clustering

Protocol deviations per 100 completed visits across a multi-site study fell from 4.6 to 2.9 over two months while randomisation accelerated. study_subject_visit carries study_id, site_id, subject_id, visit_number, visit_name, planned_visit_date, actual_visit_date, visit_window_days, visit_status, protocol_deviation_flag, deviation_severity, data_entry_ts and site_activation_date. Operations wants to credit a retraining rollout that began in that window. Establish whether deviation behaviour changed, and deliver a version of the series that is safe to review monthly.

Approach

Treat deviation flags as late-arriving data. Build a lag triangle of data_entry_ts minus actual_visit_date, because deviations are largely identified during monitoring review weeks after the visit, so the two most recent months are structurally undercounted in exactly the way an improvement looks.
Hold back the months that are not developed, or apply development factors fitted on fully developed months, and restate. Do this before any explanation involving training.
Attack the denominator. It counts visits with visit_status 'completed', while out_of_window and missed visits are excluded even though out-of-window attendance is itself a deviation in most protocols, so a site that pushes visits out of window lowers the rate twice over.
Standardise the visit mix. Newly activated sites contribute mostly screening and baseline visits, which carry fewer procedures and fewer opportunities to deviate than later treatment visits, so compute the rate within visit_number strata and reweight to a fixed mix before comparing months.
Split major from minor deviation_severity and report them separately. A single major deviation can remove a subject from the per-protocol analysis set while ten minor ones may not, so a pooled rate can fall while the consequential series rises.
Before attributing anything to training, model at the right level: subjects are nested in sites, so use a random intercept per site or cluster-robust standard errors. With average cluster size m and intracluster correlation rho the variance is understated by the design effect 1 + (m - 1) times rho, which at m = 60 and rho = 0.02 is about 2.2, so naive intervals are roughly 1.5 times too narrow.

Follow-up

Design a defensible evaluation of the retraining rollout, given it was deployed site by site and cannot be withheld.
Your reweighted series is flat but major deviations rose. What do you escalate and to whom?
How would you decide the holdback period, and how would you communicate a provisional number without it being quoted as final?

Suggested practice checklist

Roughly 90 minutes a night on weekdays with one longer weekend block. The plan deliberately cuts scope rather than compressing everything, on the assumption that finishing one thing a night beats half-starting four.

Day 1 — Fix the scope and set a baseline

Read the role description and write the three things the loop will almost certainly test, then write an explicit not-doing list for everything else and keep it visible all week.
Take one 20-minute SQL prompt and one 10-minute metric question cold, and write the single sentence that says what blocked each attempt, since that sentence is what decides which two topics get the most evenings.
Set the week's one rule: one problem finished to completion every night, including the night you only have 40 minutes.

Deliverable: A one-page scope with an explicit not-doing list and two cold attempts, each carrying one sentence on what blocked it.

Day 2 — One query pattern, written three times

Choose the single pattern most likely to appear (a cohort retention grid, or a funnel counted by user) and write it three times from a blank file rather than editing the previous attempt.
On the third attempt, write the grain of every CTE as a comment before writing its body.
Stop at 90 minutes even if the third version is imperfect, and write the one thing you would fix with another hour.

Deliverable: Three independent versions of the same query plus a note on what changed between them.

Day 3 — Only the statistics you will be asked to defend

Write, in under 200 words, how you would decide whether a difference between two groups is real: the test, its assumptions, and what you would switch to when an assumption fails.
Compute a 95 percent confidence interval for a difference in proportions by hand on realistic numbers, then write in one sentence what changes if the two samples are paired rather than independent.
Write your answer to "what does a p-value mean", check it against a definition, and delete the version that describes it as the probability the hypothesis is true.

Deliverable: A 200-word written answer and one hand-computed interval you can reproduce under pressure.

Day 4 — One case, and the assumptions holding it up

Answer one product case aloud in 20 minutes with a recording running, then listen back with a pen and mark every claim you asserted without saying what it rested on: an assumed user behaviour, an assumed data source, an assumed baseline rate, an assumed grain.
Pick the three assumptions the recommendation actually depends on, write how you would check each one against data, and say which one being wrong would flip the recommendation rather than merely weaken it.
Write the four-step structure you used onto a card small enough to hold in working memory when you are nervous.

Deliverable: One recording, three load-bearing assumptions each with a written check, and a four-step structure card.

Day 5 — Your own work, timed

Write a 90-second version and a four-minute version of your main project, and time both out loud rather than reading them.
Prepare answers to the two follow-ups that always come: what you would do differently, and how you knew it worked.
Put one number in the first sentence and be able to say exactly where that number came from and what it excludes.

Deliverable: Two timed narratives with one defensible number in the opening line.

Day 6 — The one full rehearsal, in a longer weekend block

Run a 60-minute mock covering query work, a case and a behavioural question in a single sitting with no breaks, because sustained attention is the thing evenings have not trained.
Immediately afterwards, and before hearing any feedback, write the three moments you lost the thread.
Spend the rest of the block only on those three moments, and on nothing you merely feel shaky about.

Deliverable: Mock notes naming three failure moments with a specific fix written under each.

Day 7 — Taper

Write the 20-minute warm-up you will actually do on the morning of the interview: one query you can already write from a blank file, one metric you can define out loud, and nothing you have never seen before.
Re-read only your own notes from this week, and open no new material.
Write down the logistics: the tool you will be asked to work in, whether lookups are allowed, and the sentence you will use when you do not know something.

Deliverable: A one-page card holding the case structure, the project numbers, and the logistics.

Explaining a method to someone who will not follow the maths

Half of this section is about translation. Be ready to describe how you explained a result to someone who did not want the method, only the implication, and what you did when the simplified version started being repeated in a way that overstated it. Correcting your own simplification is a strong beat.

How do you handle conflicts within a team, especially when data interpretations differ?

Medium · behavioural and stakeholder questions

Approach

Close with what you would do differently, concretely.
State the situation in two sentences and spend the rest on your reasoning.
Pick a story where you drove the decision, not one where you observed it.

Follow-up

What would you do differently if you ran that project again?
What did you decide not to do, and why?

Describe a time when you had to persuade a team to adopt your data-driven recommendation. What was your approach?

Medium · behavioural and stakeholder questions

Approach

Name the disagreement or constraint, and how you resolved it with evidence.
Close with what you would do differently, concretely.
Pick a story where you drove the decision, not one where you observed it.

Follow-up

What did you decide not to do, and why?
What would you do differently if you ran that project again?

Make an honest case for your own analytical impact

Hard · impact attribution · counterfactual · self-assessment

You are asked to account for a year of your work. Constraint: you may only use measures that existed before you knew the outcome, and you must include one project that moved nothing. The portfolio contains a measure specification that changed how a contract settles, a predictive model that shipped, a self-serve dashboard, and an evaluation that killed a proposed programme. Deliverable: how you attribute value to each, which of them you claim credit for and which you do not, and the one number you would accept being judged on next year.

Approach

The probe is whether you can reason counterfactually about your own work, which is the same discipline this domain demands of you for programmes, applied where it is uncomfortable.
State the counterfactual for each item: what would have happened without you. A measure specification that changed how a contract settles has a dollar counterfactual you can compute. A dashboard's counterfactual is analyst hours, which is real and small, and attaching a revenue number to it is where these accounts usually turn into fiction.
Treat the killed programme as your strongest item and say why. Avoided spend is real value, it is attributable because the decision turned on your evaluation, and it is the one item nobody else will count on your behalf.
Report the shipped model the way you would report anyone's model: calibration in the subgroups that matter, adoption by the people it was built for, and whether any decision changed. A model that is live but ignored has zero impact, and saying so is the credibility test in this answer.
Name the failed project with its mechanism and its cost, then say what earlier signal you would watch to kill it sooner. Time to kill is a legitimate impact measure.
Choose next year's number so that it can go down. A metric that only ratchets upward is not a commitment.

Follow-up

Two other people also claim the contract measure. How do you split it?
Your model is live and used, but the decisions it informs would have been the same without it. Is that impact?
What is the strongest argument that your year had less impact than you just described?